

## Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	25.3	114.8	(76.8-164.8)	Male	20	14.6	136.7	(83.5-211.2)
Female	4	8.9	nc	(nc-nc)	Female	10	11.7	85.4	(40.9-157.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.1	138.5	(55.5-285.3)	Male	3	3.9	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	16	13.1	121.9	(69.6-198.0)
Female	103	95.7	107.6	(87.8-130.5)	Female	13	11.5	113.3	(60.3-193.8)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
					Male	7	10.2	68.9	(27.6-142.0)
Female	7	4.3	164.2	(65.8-338.3)	Female	5	4.6	109.3	(35.2-255.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	30	38.3	78.4	(52.9-111.9)	Female	4	10.2	nc	(nc-nc)
Female	38	33.5	113.4	(80.3-155.7)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	6.8	103.2	(41.3-212.5)	Male	2	7.3	nc	(nc-nc)
Female	4	1.7	nc	(nc-nc)	Female	9	7.3	123.1	(56.2-233.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.0	nc	(nc-nc)	Male	116	110.0	105.5	(87.2-126.5)
Female	1	1.6	nc	(nc-nc)					
<u>Kidney &amp; Renal Pelvis</u>					<u>Stomach</u>				
Male	8	11.3	70.5	(30.4-139.0)	Male	8	6.4	125.3	(54.0-246.9)
Female	5	6.7	74.2	(23.9-173.2)	Female	3	3.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	6	4.5	133.2	(48.6-289.9)	Male	4	3.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	9	8.1	111.2	(50.7-211.1)	Male	2	3.2	nc	(nc-nc)
Female	10	6.2	162.3	(77.7-298.5)	Female	18	10.0	179.3	(106.2-283.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.5	nc	(nc-nc)	Female	18	20.6	87.2	(51.7-137.8)
Female	0	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	45	49.3	91.3	(66.6-122.2)	Male	351	352.3	99.6	(89.5-110.6)
Female	48	44.4	108.2	(79.8-143.5)	Female	329	314.6	104.6	(93.6-116.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;